Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Atezolizumab is already approved for use in non–small cell lung cancer (NSCLC) as well as bladder cancer and was recently approved for use in triple-negative breast cancer.

In the U.S., approximately 13 percent of lung cancers are small cell. 2 Approximately 30,000 new cases of small cell lung cancer (SCLC) are reported in the U.S. each year. 2, 3 The risk for ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ...

Researchers are specifically studying the drug atezolizumab for non-small cell lung cancer. "It can now be given as a subcutaneous injection under the skin, which is a heck of a lot easier for people.

HealthDay News — Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance ...

About Small Cell Lung Cancer In the U.S., approximately 13 percent of lung cancers are small cell.ii Approximately 30,000 new cases of small cell lung cancer (SCLC) are reported in the U.S. each ...

Atezolizumab With Platinum and Etoposide Chemotherapy Followed by Cystectomy for Patients With Localized Small Cell Neuroendocrine Bladder Cancer – An ASCO Reading Room selection November 30, 2023 ...

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab ... "In the U.S., approximately 30,000 new cases of small cell lung cancer are diagnosed each year, ...

Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ...